Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin

Drug Metabolism and Disposition

Volumn 38, Issue 9, 2010, Pages 1499-1504

  Amundsen, Rune ^a   Christensen, Hege ^a   Zabihyan, Behnaz ^a   Åsberg, Anders ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYCLOSPORIN A; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; EMBRYO; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; ORGAN TRANSPLANTATION; PRIORITY JOURNAL;

CELL LINE; CYCLOSPORINE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; ORGANIC ANION TRANSPORTERS; PYRROLES; TACROLIMUS;

EID: 77955994141     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032268     Document Type: Article

References (44)

1. Aakhus S, Dahl K, and Widerøe T (1999) Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14:648-654.
2. Akhlaghi F, McLachlan AJ, Keogh AM, and Brown KF (1997) Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 44:537-542.
3. Akhlaghi F and Trull AK (2002) Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 41:615-637.
4. Asberg A (2003) Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63:367-378.
5. Asberg A, Falck P, Undset LH, Dørje C, Holdaas H, Hartmann A, and Midtvedt K (2010) Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study. Ther Drug Monit 32:152-158.
6. Asberg A, Hartmann A, Fjeldså E, Bergan S, and Holdaas H (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 1:382-386.
7. Atkinson K, Britton K, and Biggs J (1984) Distribution and concentration of cyclosporin in human blood. J Clin Pathol 37:1167-1171.
8. Bachmann KA and Lewis JD (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072.
9. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless JP, and Stein EA (2003) Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163:553-564.
10. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
11. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, and Smolarek TA (2005) Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537-546.
12. Christensen H, Baker M, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci 95:2778-2787.
13. Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, Pfeffer P, Hartmann A, and Midtvedt K (2008) Declining intracellular T-lymphocyte concentration of cyclosporine A precedes acute rejection in kidney transplant recipients. Transplantation 85:179-184.
14. Falck P, Guldseth H, Asberg A, Midtvedt K, and Reubsaet JL (2007) Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 852:345-352.
15. Fehrenbach T, Cui Y, Faulstich H, and Keppler D (2003) Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 368:415-420.
16. Hermann M, Asberg A, Christensen H, Holdaas H, Hartmann A, and Reubsaet JL (2004) Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 76:388-391.
17. Hermann M, Christensen H, and Reubsaet JL (2005) Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 382:1242-1249.
18. Hinton LK, Galetin A, and Houston JB (2008) Multiple inhibition mechanisms and prediction of drug- drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil- drug interactions. Pharm Res 25:1063-1074.
19. Holdaas H, Hagen E, Asberg A, Lund K, Hartman A, Vaidyanathan S, Prasad P, He YL, Yeh CM, Bigler H, et al. (2006) Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 44:163-171.
20. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
21. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
22. Jones P, Kafonek S, Laurora I, and Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587.
23. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, and Mekki QA (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57:281-290.
24. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
25. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, and Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522.
26. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, et al. (2003) The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein - quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372.
27. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, and Sugiyama Y (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891-1901.
28. Kusuhura H and Sugiyama Y (2002) Drug-drug interactions involving the membrane transport process, in Drug-Drug Interactions (Rodrigues AD ed) pp 123-188, Marcel Dekker Inc., New York.
29. Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34:1175-1181.
30. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, and Maes BD (2005) Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5:2236-2243.
31. Macarrón R and Hertzberg RP (2002) Design and implementation of high throughput screening assays, in High Throughput Screening: Methods and Protocols (Janzen WP ed) pp 1-30, Humana Press Inc., Totowa, NJ.
32. Niwa T, Yamamoto S, Saito M, Shiraga T, and Takagi A (2007) Effect of cyclosporine and tacrolimus on cytochrome P450 activities in human liver microsomes. Yakugaku Zasshi 127:209-216.
33. Nozawa T, Minami H, Sugiura S, Tsuji A, and Tamai I (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10- hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434-439.
34. Piñeyro-López A, Piñeyro-Garza E, Torres-Alanís O, Reyes-Araiza R, Gómez-Silva M, Waksman N, E Salazar-Leal M, and Luján-Rangel R. Salazar-Leal M, and Luján-Rangel R (2007) Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers. Clin Ther 29:2049-2054.
35. Sam WJ, Tham LS, Holmes MJ, Aw M, Quak SH, Lee KH, Lim SG, Prabhakaran K, Chan SY, and Ho PC (2006) Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet 45:59-75.
36. Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, and Horie T (2009) Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin A in rats. Drug Metab Dispos 37:1172-1178.
37. Skalicka B, Kubanek M, Malek I, Vymetalova Y, Hoskova L, Podzimkova M, and Kautzner J (2009) Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin. J Heart Lung Transplant 28:598-604.
38. Smith NF, Figg WD, and Sparreboom A (2005) Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 1:429-445.
39. Taylor PJ, Brown SR, Cooper DP, Lynch SV and Pillans PI (2007) A High-Throughput LC/MS/MS Method for Tacrolimus Measurement in Kidney and Liver Transplant Patients. Waters, Milford, MA.
40. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, and Wood AJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59: 3944-3948.
41. Wang XQ, Dai JD, Chen Z, Zhang T, Xia GM, Nagai T, and Zhang Q (2004) Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Release 97:421-429.
42. Yang ZQ, Xu J, Pan P, and Zhang XN (2009) Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticle formulation and its pharmacokinetic profile in rats. Pharmazie 64:26-31.
43. Zaghloul I, Ptachcinski RJ, Burckart GJ, Van Thiel D, Starzel TE, and Venkataramanan R (1987) Blood protein binding of cyclosporine in transplant patients. J Clin Pharmacol 27:240-242.
44. Zahir H, Nand RA, Brown KF, Tattam BN, and McLachlan AJ (2001) Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods 46:27-35.